Start
Entdecken
nav.journalClub
Trends
Mehr
Synapse
⌘+K
Synapse
Sprache
Deutsch
Deutsch
Table S1. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer | Synapse
September 16, 2025
View Full Paper
Table S1. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer
RY
Rona Yaeger
Memorial Sloan Kettering Cancer Center
JM
Jean-François Martini
Pfizer (United States)
LP
Lincoln W. Pasquina
Boston Foundation
See all
Key Points
Assessment reveals significant clinical validity for detecting BRAF V600E in colorectal cancer patients.
Data indicates a substantial representation of the patient population analyzed for BRAF V600E.
Methodology includes clinical validity assessment focusing on DNA-based diagnostics.
Findings support the use of liquid biopsy techniques for effective cancer mutation detection.
Abstract
Representativeness of the patient population analyzed.
KI fragen
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
KI fragen
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Yaeger et al. (Tue,) studied this question.
synapsesocial.com/papers/68d4565b31b076d99fa5b18a
https://doi.org/https://doi.org/10.1158/2767-9764.30083889